ertiprotafib has been researched along with Diabetes Mellitus, Type 2 in 4 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bombrun, A; Hooft van Huijsduijnen, R; Sauer, WH; Swinnen, D | 1 |
| Bhattarai, BR; Cho, H; Choi, JK; Shrestha, S | 1 |
| Bhattarai, BR; Cheon, HG; Cho, H; Ham, SW; Kim, KR; Lee, KH; Shrestha, S | 1 |
| Erbe, DV; Furey, S; Harding, K; Klaman, LD; Kung, L; Qadri, A; Stolz, L; Tam, M; Tobin, JF; Wang, S; Xing, Y; Zhang, YL | 1 |
1 review(s) available for ertiprotafib and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Obesity; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases | 2004 |
1 trial(s) available for ertiprotafib and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; I-kappa B Kinase; Phenylpropionates; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Thiophenes | 2007 |
2 other study(ies) available for ertiprotafib and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity.
Topics: Animals; Blood Glucose; Cell Membrane Permeability; Diabetes Mellitus, Type 2; Dietary Fats; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Kinetics; Male; Mice; Mice, Inbred C57BL; Protein Tyrosine Phosphatases; Structure-Activity Relationship | 2007 |
Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.
Topics: Adipocytes; Animals; Blood Glucose; Cell Differentiation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Kinetics; Lipids; Male; Mice; Mice, Obese; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Recombinant Proteins; Thiophenes; Triglycerides | 2005 |